An investigational RNAi therapeutic targeting Factor XII (ALN-F12) for the treatment of hereditary angioedema

FXII dose-dependent HK cleavage in human plasma. Normal human pooled plasma was mixed with FXII-deficient (<1%) human plasma at different ratios to generate different concentration of FXII in the mixture. The plasma mixtures were activated under mild conditions (0.2 µg/mL Kaolin, 37°C, 10 min) and loaded into SDS-PAGE for western blot analysis. The anti-HK antibody detects the intact, full-length HK. The uncleaved full-length HK signal ratio of kaolin treatment to no kaolin treatment is represented in Table 1 below.